We’re excited to announce that Linda Rhodes, VMD, PhD has joined our Board of Directors. Dr. Rhodes is a scientist, veterinarian, entrepreneur, and leader in animal health, and we’re lucky to welcome her to the Loyal team. Read more from our Founder and CEO Celine Halioua on our blog https://lnkd.in/gUrQ_EhF.
Loyal
Biotechnology Research
San Francisco, CA 6,993 followers
Loyal is developing the first-ever drugs intended to extend the healthspan and lifespan of dogs.
About us
Loyal is a clinical-stage veterinary medicine company developing drugs intended to extend the lifespan and healthspan of dogs. In other words, our mission is to help dogs live longer, healthier lives. We’ve already achieved significant milestones on our path to gaining FDA approval for the first lifespan extension drug for any species. We have three products in our pipeline and are on track to bring the first product to market in 2025. Our team includes scientists, veterinarians, engineers, operators, and creatives. Join us in our mission to help dogs everywhere.
- Website
-
loyal.com
External link for Loyal
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
San Francisco, CA 94103, US
Employees at Loyal
Updates
-
Caloric restriction has been shown to extend dogs’ lifespans and improve their metabolic health but can be difficult to sustain long-term. Fortunately, there are more practical alternatives to caloric restriction—like what we’re working on at Loyal—that mimic these positive effects. Read our full blog post at https://loyal.dog/CR.
-
Thank you, Daniel Promislow and Elliot Gerson (The Aspen Institute), for such an engaging conversation at the #AspenIdeas Festival this afternoon. Always exciting when some of our canine friends join in, too!
-
-
We’re excited to share that our CEO and Founder Celine Halioua will be speaking at the Aspen Ideas Festival tomorrow: → ‘New Leash on Life: Is Dog Longevity the Key to Ours?’ on June 25 at 1:50 p.m. MT She's joining Daniel Promislow and Elliot Gerson (The Aspen Institute) and will share insights on how Loyal is helping dogs live longer, healthier lives. #AspenIdeas
-
-
Loyal reposted this
Great convo with Linda Rhodes, VMD, PhD, Duncan Mackintosh, + David Haworth, DVM, PhD on building animal drug biotech companies and the translation of dog biology --> human biology. save the dogs, save the world :)
-
-
We’re attending #AVMA2024 to talk with vets on how we’re developing drugs to extend healthy lifespan in dogs. Meet our vet team at booth 141 to learn more and receive a thank-you gift for stopping by. We’re also sponsoring a CE session presented by our Director of Veterinary Medicine, Dr. Brennen McKenzie, on Sunday at 3PM. He’ll discuss the role of aging as a modifiable risk factor for health problems seen in geriatric dogs and what vets can do about it to help their patients. #VeterinaryMedicine #CanineAging
-
Thanks, Animal Health Innovation, for including us today!
Returning for day 2 at #AHNTIUSA Linda Rhodes, VMD, PhD leads our Human Animal Translation panel exploring models for animal health therapies from the human health space. Thank you to Celine Halioua (Loyal), David Haworth, (Embark Veterinary) and Duncan Mackintosh (Brandon Capital) for providing their insight on the opportunities, challenges and risks found across both markets. #AnimalHealth #Innovation
-
-
We’re still here for the dogs! Check out our new domain: https://loyal.com/
-
-
Could your dog be the future face of our first FDA-approved lifespan extension drug? If your dog is over 10 years old and at least 14 lb, or over 7 years old and at least 40 lb, we’d love to consider them! Please note that you must be able to get to Orlando / Tampa and be available 5/15-5/17. To be considered, fill out the form at https://lnkd.in/gFAcS7Q4
-
Did you know the FDA allows conditional approval for animal drugs that meet an unmet need? In situations where demonstrating effectiveness for these drugs would require particularly complex studies, a drug can get conditional approval by presenting extensive data to the FDA in three core areas: → Full safety data, → Full manufacturing data, and → Reasonable expectation of effectiveness. Learn more about what this means for our products → https://lnkd.in/gSBgmBNk
-